Why are people thinking so sequentially about our
Post# of 155139
(Total Views: 678)
Posted On: 10/26/2020 1:12:48 PM
Re: jamming1092 #63185
Why are people thinking so sequentially about our pathway to final approval?
During this pandemic, pathways have been made to accelerate the whole process. Sure a lot of people are waiting for Covid trial data but that doesn't mean that the steps to approval that the Center for Drug Evaluation and Research (CDER) normally does can't be done beforehand.
This is what OWS and other programs are all about. To all of these programs the Interim Data can and, hopefully, has been unblinded. These programs may be working as we speak to put in place emergency funding, manufacturing, distribution, etc. I suspect they are.
I believe that what we shareholders should be doing, if so motivated, is to see that these non-sequential steps are indeed being taken ASAP.
Our therapeutic should be taken as seriously as any f'ing vaccine candidate out there!
We should have an order from the gov't for billions of doses of Leronlimab; we should be getting help with getting Leronlimab manufactured; we should have gov't officials working on the widest and fastest distribution of Leronlimab when it becomes available and triage strategies for the earliest batches of product should have all been worked out.
I have no doubt that Leronlimab will come through its trials with flying colors. It is just a matter of time. I am worried about the strategic questions that must be solved after the trials. That is what we should be concentrating on, making sure that our pathway to success is as greased as it is for all our competitors.
And we are the one who deserve it THE MOST because Leronlimab kicks butt better than anything else out there! Is there any doubt about that? Not from me!
During this pandemic, pathways have been made to accelerate the whole process. Sure a lot of people are waiting for Covid trial data but that doesn't mean that the steps to approval that the Center for Drug Evaluation and Research (CDER) normally does can't be done beforehand.
This is what OWS and other programs are all about. To all of these programs the Interim Data can and, hopefully, has been unblinded. These programs may be working as we speak to put in place emergency funding, manufacturing, distribution, etc. I suspect they are.
I believe that what we shareholders should be doing, if so motivated, is to see that these non-sequential steps are indeed being taken ASAP.
Our therapeutic should be taken as seriously as any f'ing vaccine candidate out there!
We should have an order from the gov't for billions of doses of Leronlimab; we should be getting help with getting Leronlimab manufactured; we should have gov't officials working on the widest and fastest distribution of Leronlimab when it becomes available and triage strategies for the earliest batches of product should have all been worked out.
I have no doubt that Leronlimab will come through its trials with flying colors. It is just a matter of time. I am worried about the strategic questions that must be solved after the trials. That is what we should be concentrating on, making sure that our pathway to success is as greased as it is for all our competitors.
And we are the one who deserve it THE MOST because Leronlimab kicks butt better than anything else out there! Is there any doubt about that? Not from me!
(7)
(0)